lanicemine
Small moleculeexperimental
Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013. — Wikipedia
Clinical trial activity
11 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2007 (NCT00491686)
Timeline
Indications
Mechanism of action
- Glutamate [NMDA] receptorBLOCKER
Glutamate [NMDA] receptor blocker
Non-selective, open-channel blocker.
- Glutamate receptor ionotropic, NMDA 1 (GRIN1) ↗
- Glutamate receptor ionotropic, NMDA 2A (GRIN2A) ↗
- Glutamate receptor ionotropic, NMDA 2B (GRIN2B) ↗
- Glutamate receptor ionotropic, NMDA 2D (GRIN2D) ↗
- Glutamate receptor ionotropic, NMDA 3B (GRIN3B) ↗
- Glutamate receptor ionotropic, NMDA 2C (GRIN2C) ↗
- Glutamate receptor ionotropic, NMDA 3A (GRIN3A) ↗
- Glutamate (NMDA) receptor subunit zeta 1
- Glutamate [NMDA] receptor subunit epsilon 1
- Glutamate [NMDA] receptor subunit epsilon 2
- Glutamate [NMDA] receptor subunit 3A
- Glutamate [NMDA] receptor subunit epsilon 4
- Glutamate [NMDA] receptor subunit epsilon 3
- Glutamate NMDA receptor; GRIN1/GRIN2B
- Glutamate NMDA receptor; GRIN1/GRIN2A
- Ionotropic glutamate receptor NMDA 1/2C
- Ionotropic glutamate receptor NMDA 1/2D
- Glutamate NMDA receptor; GRIN1/GRIN2A/GRIN2B
- Glutamate receptor ionotropic, NMDA 1/2C/3B
Chemistry & pharmacology
Loading structure…
SMILES
N[C@@H](Cc1ccccn1)c1ccccc1- Mol. weight
- 198.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL467084 ↗
- WikipediaLanicemine ↗
- ChEMBLCHEMBL2107647 ↗
Also known as
- azd6765
- azd6765
- azd6765
- azd-6765
- azd-6765
- lanicemine
- lanicemine
- lanicemine
- lanicemine
- lanicemine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03166501 | Phase 1 | Sep 1, 2017 | Baylor University, National Institute of Mental Health (NIMH) |
| NCT01482221 | Phase 2 | Dec 16, 2011 | AstraZeneca |
| NCT01217645 | Phase 1 | Sep 1, 2010 | AstraZeneca, IQVIA |
| NCT01130909 | Phase 1 | May 1, 2010 | AstraZeneca, Forenap Pharma |
| NCT01069822 | Phase 1 | Feb 1, 2010 | AstraZeneca, IQVIA |
| NCT01046630 | Phase 1 | Dec 1, 2009 | AstraZeneca, University of Manchester, University of Oxford |
| NCT00986479 | Phase 2 | Dec 1, 2009 | AstraZeneca, National Institute of Mental Health (NIMH) |
| NCT00963365 | Phase 1 | Nov 1, 2008 | AstraZeneca, IQVIA |
| NCT00785915 | Phase 1 | Nov 1, 2008 | AstraZeneca, California Clinical Trials |
| NCT00781742 | Phase 2 | Oct 1, 2008 | AstraZeneca, Yale University |
| NCT00491686 | Phase 2 | Jul 1, 2007 | AstraZeneca |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 10 | 10 | 2 | 2007 |
| IQVIA | For profit | 3 | 0 | 1 | 2008 |
| National Institute of Mental Health (NIMH) | Government | 2 | 0 | 2 | 2009 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| California Clinical Trials | For profit | 1 | 0 | 1 | 2008 |
| Forenap Pharma | For profit | 1 | 0 | 1 | 2010 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2008 |
9 organizations
Page 1 / 1